LifeMD
LFMD
Market cap $566M

12.46 USD

-0.24

1.89%

At close Jun 13, 4:00 PM EDT

After hours

12.34

-0.12

0.96%

1 day

-1.89%

5 days

-2.04%

1 month

46.24%

3 months

120.14%

6 months

118.98%

Year to date

138.24%

1 year

53.45%

5 years

58.73%

10 years

58.73%

About: LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.

Employees: 336

Healthcare Health Information Services

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

22% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 32

13% more capital invested

Capital invested by funds: $79.3M [Q4 2024] → $89.7M (+$10.3M) [Q1 2025]

0.03% less ownership

Funds ownership: 37.01% [Q4 2024] → 36.98% (-0.03%) [Q1 2025]

3% less funds holding

Funds holding: 105 [Q4 2024] → 102 (-3) [Q1 2025]

11% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 19

70% less call options, than puts

Call options by funds: $1.1M | Put options by funds: $3.68M

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$14

12%

upside

Avg. target

$14

12%

upside

High target

$14

12%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Yi Chen

12%upside

$14

Buy

Reiterated

30 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about LFMD published over the past 30 days

LifeMD to Participate in Two Investor Conferences During June

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of June: BTIG Obesity Health Forum, June 18. Management will participate in a virtual panel discussion titled “Direct to Consumer vs.

LifeMD to Participate in Two Investor Conferences During June

LifeMD: Growth, Growth, And More Growth

LifeMD is experiencing a major growth inflection, with record Q1 revenue, first-ever GAAP profitability, and strong subscriber and margin gains. Multiple growth drivers - including GLP-1 programs, Medicare expansion, AI automation, and a women's health acquisition - support a robust multi-year growth outlook. Valuation is high on earnings metrics but discounted on sales multiples. Significant upside exists if LifeMD sustains revenue growth and achieves positive EPS.

LifeMD: Growth, Growth, And More Growth

Top 2 Health Care Stocks That May Implode In Q2

As of May 23, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 2 Health Care Stocks That May Implode In Q2

LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®

Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter

LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®

LifeMD to Participate in Three Investor Conferences During May

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May:

LifeMD to Participate in Three Investor Conferences During May

LifeMD, Inc. (LFMD) Q1 2025 Earnings Call Transcript

LifeMD, Inc. (NASDAQ:LFMD ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Justin Schreiber - Chairman and CEO Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG Sarah James - Cantor Fitzgerald Steve Dechert - KeyBanc Steven Valiquette - Mizuho Securities Yi Chen - H.C. Wainwright Anderson Schock - B.

LifeMD, Inc. (LFMD) Q1 2025 Earnings Call Transcript

Zacks Investment Research

LifeMD, Inc. (LFMD) Q1 Earnings and Revenues Top Estimates

LifeMD, Inc. (LFMD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.19 per share a year ago.

LifeMD, Inc. (LFMD) Q1 Earnings and Revenues Top Estimates

LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance

Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70% Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period Telehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million in the year-ago period GAAP net income of $0.6 million or $0.01 per diluted share, delivering first-ever quarter of positive GAAP EPS Raising full-year 2025 guidance for both total revenues and adjusted EBITDA, reflecting strong year-to-date performance in telehealth Conference call begins at 4:30 p.m. Eastern time today NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three months ended March 31, 2025.

LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance

The Motley Fool

Why Hims & Hers Health and LifeMD Are Skyrocketing Today

Shares of Hims & Hers Health (HIMS 25.46%) and LifeMD (LFMD 35.41%) are surging on Tuesday. The companie' stocks had jumped 24% and 34%, respectively, as of 3:15 p.m.

Why Hims & Hers Health and LifeMD Are Skyrocketing Today

LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD's virtual care platform.

LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients

See News Rankings

Charts implemented using Lightweight Charts™